Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.70 |
| ▸ | GNPAT | O15228 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.45 |
| ▸ | CCKAR | P32238 | 4/20 | 0.43 |
| ▸ | CCKBR | P32239 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806536 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL8248469 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL16948269 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL14114131 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL12296711 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL24486694 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL12806481 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL18573658 | 1.00 | GLP1R (0.70) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL17401206 | 0.99 | GLP1R (0.69) | GLP1RGNPATFOLH1NOD1CCKAR | |
| SCHEMBL18551953 | 0.99 | GLP1R (0.69) | GLP1RGNPATFOLH1NOD1CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016319-A1 | Acylated Glucagon Analogues | NOVO NORDISK AS (DK) | 2018-01-18 | — | — | US | disclosed |
| US-20170190757-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-07-06 | — | — | US | disclosed |
| US-20170051034-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2017-02-23 | — | — | US | disclosed |
| US-20160271263-A1 | Acylated Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-09-22 | — | — | US | disclosed |
| US-20160002311-A1 | Novel Glucagon Analogues | NOVO NORDISK AS (DK) | 2016-01-07 | — | — | US | disclosed |
| US-9150633-B2 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2015-10-06 | — | — | US | disclosed |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-9045560-B2 | Protease stabilized, acylated insulin analogues | NOVO NORDISK A/S (DK) | 2015-06-02 | — | — | US | disclosed |
| US-8853155-B2 | Insulin derivatives containing additional disulfide bonds | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| EP-2708554-A1 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2014-03-19 | — | — | EP | disclosed |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2014-03-13 | — | — | US | disclosed |
| WO-2011117415-A1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK A/S (DK) | 2011-09-29 | — | — | WO | disclosed |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
| WO-2009022013-A1 | INSULIN ANALOGUES WITH AN ACYL AND AKLYLENE GLYCOL MOIETY | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009022005-A1 | INSULIN ANALOGUES WITH AN ACYL AND ALKYLENE GLYCOL MOIETY | NOVO NORDISK A/S (DK) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190757-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885GNPAT 1392/4885FOLH1 303/4885 |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | IAPP, INSR, IGF1R | GLP1R 7/4885GNPAT 2340/4885FOLH1 1261/4885 |
| US-20140073564-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 84/4885GNPAT 1248/4885FOLH1 408/4885 |
| US-20180016319-A1 | Acylated Glucagon Analogues | GLP1R, GCG, IAPP | GLP1R 1/4885GNPAT 304/4885FOLH1 352/4885 |
| US-20160002311-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885GNPAT 1392/4885FOLH1 303/4885 |
| US-20160271263-A1 | Acylated Glucagon Analogues | GLP1R, GCG, IAPP | GLP1R 1/4885GNPAT 304/4885FOLH1 352/4885 |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 54/4885GNPAT 1212/4885FOLH1 524/4885 |
| US-20170051034-A1 | Novel Glucagon Analogues | GLP1R, GIPR, IAPP | GLP1R 1/4885GNPAT 1392/4885FOLH1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.